G484S amino acid substitution in lanosterol 14-alpha demethylase (ERG11) is related to fluconazole resistance in a recurrent Cryptococcus neoformans clinical isolate by Rodero, Laura et al.
This is the peer reviewed version of the following article:
G484S Amino Acid Substitution in Lanosterol 14-α Demethylase (ERG11) Is Related to 
Fluconazole Resistance in a Recurrent Cryptococcus neoformans Clinical Isolate
Laura Rodero, Emilia Mellado, A. Carolina Rodriguez, Angela Salve, Liliana Guelfand,
Pedro Cahn, Manuel Cuenca-Estrella, Graciela Davel, and Juan L. Rodriguez-Tudela.
Antimicrob Agents Chemother. 2003 Nov;47(11):3653-6.
which has been published in final form at
https://doi.org/10.1128/aac.47.11.3653-3656.2003
1
Running Title: ERG11 mutation in a fluconazole-resistant C. neoformans.
G484S Amino Acid Substitution of 14- lanosterol demethylase (ERG11)
Related to Fluconazole Resistance in a Recurrent Cryptococcus neoformans
Clinical Isolate.
Laura Rodero*1, Emilia Mellado*2, A. Carolina Rodriguez1, Angela Salve1, Liliana
Guelfand3, Pedro Cahn3, Manuel Cuenca-Estrella2, Graciela Davel1, Juan L Rodriguez-
Tudela 2.
*L.R. and E. M. contributed equally to this work.
1 Departamento Micología. Instituto Nacional de Enfermedades Infecciosas. ANLIS “Dr.
Carlos G. Malbrán”. Buenos Aires. Argentina.
2 Unidad de Micología. Centro Nacional de Microbiología. Instituto de Salud Carlos III.
Majadahonda. Spain.
3 Hospital J. A. Fernandez. Buenos Aires. Argentina.
Corresponding author:
Laura Rodero. Departamento Micología. Instituto Nacional de Enfermedades
Infecciosas. ANLIS “Dr. Carlos G. Malbrán”. Av. Velez Sarsfield 563. (1281) Buenos
Aires. Argentina. e-mail: lrodero@anlis.gov.ar Fax/Phone: +54-11-4302-5066.
Abstract
Five sequential isolates of Cryptococcus neoformans were recovered from an AIDS
patient with recurrent episodes of meningitis and long fluconazole exposure. Isolates
1st to 4th were fluconazole susceptible and the fifth isolate had a MIC of 16 g/ml. PCR
amplification and sequencing of the gene encoding 14-lanosterol demethylase
showed a point mutation responsible for the amino acid substitution G484S in the
resistant strain only.
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Cryptococcal meningitis or meningoencephalitis is the most frequent encountered
manifestation of infections due to C. neoformans. Treatment, in patients with AIDS, can
be complicate owing to the severe immunosuppression. There is a very high relapse
rate after receiving standard regimens of amphotericin B, and this finding have led to
the use of lifelong chronic suppressive therapy. The current recommendations for
maintenance treatment is oral fluconazole (15). Long term usage of fluconazole for
fungal infections has been documented in several studies as a cause of emergence of
azole resistance. Paugam et al. and Friese et al. have reported cases of recurrent
cryptococcosis during the period of chronic suppressive therapy. Sequential isolates
from these patients were found to have increased fluconazole MICs (4;11).
Mechanisms of azole resistance in yeasts already described include altered affinity of
the 14- lanosterol demethylase (ERG11) to azole drugs due to target site mutation or
its overexpression, and decreased accumulation of drugs due to enhanced energy-
dependent drug efflux (8;18). The biochemical basis of fluconazole resistance in C.
neoformans have been explored focusing specially in the reduction of azole cellular
content and the altered activity of ERG11 (7). Changes in the azole affinity for the
ERG11 have been already related to low-level fluconazole resistance in C. neoformans
isolates (20). In addition, the decrease affinity of ERG11 for azole derivatives due to
mutations that contributes to increase the MICs of fluconazole, has been described in
sequential clinical isolates of Candida albicans (8;9). To elucidate if this mechanism
could also be implicated in C. neoformans azole resistance, we compared the ERG11
genomic sequence in five sequential isolates recovered from recurrent episodes of
cryptococcal meningitis. The first four isolates were fluconazole susceptible, and the
fifth strain was in vitro resistant.
Clinical case: The five strains of C. neoformans were isolated from a 33 year-old male
patient, HIV positive since 1990, presenting advanced AIDS (CD4+ count <100
cells/mm3) and recurrent cryptococcosis. The first episode of cryptococcosis was
diagnosed in August of 1997, at Hospital Fernandez, Buenos Aires, Argentina. During
the following 15 months, four more episodes of cryptococcal meningitis (CM) were
detected and documented by cultures recovered from cerebrospinal fluid (CSF). In all
episodes the titer of C. neoformans CSF-antigen was determined (Latex Cryptococcus
Antigen Detection System, Immuno-Mycologics, Inc. OK, USA). The first episode
(strain CN-1) showed a CSF-antigen titer (AT) of 1:4096 and the patient was treated
with 0.7 mg/kg/day of parenteral amphotericin B for two weeks. After that, a treatment
of 0.7 mg/kg/day, three times a week was prescribed, but the patient failed to comply
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with it after three weeks of therapy. Fifteen days later (October 1997), he was
hospitalized with a second episode (strain CN-2), with a CSF-AT of 1:1024. Therapy
established at this moment was amphotericin B (0.7 mg/kg/day) combined with oral
fluconazole (800 mg/day) during a month. In spite of it, the patient showed clinical
signs of meningitis, and the third isolate was recovered from de CSF (strain CN-3). No
changes were observed in the CSF-AT, and therapy was intensified with parenteral
fluconazole, with doses of 1600 mg/day during 15 days. After that, a fluconazole
maintenance therapy of 800 mg/day was established. Six months after (June 1998),
the four episode occurred (strain CN-4) with no variations at the CSF-AT, and
parenteral fluconazole was prescribed (1200 mg/day for a month). The patient
recovered again and fluconazole suppressive therapy was re-established. However,
another relapse occurred in November of 1998 (strain CN-5) without changes at the
CSF-AT (1:1024). A new treatment with parenteral amphotericin B was prescribed, but
the patient failed to comply with the therapy and left the hospital. He did not attend
Hospital Fernandez for other medical examinations. The five isolates from each
episode were identified as C. neoformans var. grubii by the following parameters:
morphology, assimilation and fermentation of carbon and nitrogen compounds and
molecular taxonomy.
Susceptibility testing of the five C. neoformans isolates were performed by
microdilution and E-test methods. Candida parapsilosis ATCC22019 and Candida
krusei ATCC6258 were used as quality control strains throughout the experiments (10).
Microdilution method: The susceptibility testing followed the NCCLS
recommendations (10) for the microdilution procedure but included some modifications
previously described (14). Briefly, the susceptibility testing included RPMI
supplemented with 2% glucose as assay medium (RPMI-2%-glucose), inoculum size
of 105 CFU/ml, flat-bottomed trays, and spectrophotometric reading. All microplates
were wrapped with film sealer to prevent the medium from evaporating, they were
attached to an electrically driven wheel inside the incubator at 30ºC, and agitated at
350 rpm for 48 h (14). The antifungal agents used in the study were as follows:
Amphotericin B (AMB) (Sigma Aldrich Quimica S.A., Madrid, Spain), 5-flucytosine
(5FC) (Sigma Aldrich Quimica), fluconazole (FCZ) (Pfizer S.A:, Madrid, Spain),
itraconazole (ITZ) (Janssen S.A., Madrid, Spain) and voriconazole (VOR) (Pfizer S.A.).
The MICs were determined at 24 and 48 h spectrophotometrically. MICs were
obtained measuring the absorbance at 530 nm with a MRXII reader (Dynatech, Cultek,
Madrid, Spain). For AMB the MIC endpoints were defined as the lowest drug
concentration exhibiting reduction in growth of 90% or more compared with that of the
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control growth. For flucytosine and azole drugs the MIC endpoint was defined as the
lowest drug concentration exhibiting a reduction in growth of 50% or more compared
with that of the control growth.
E-test method: Tests were performed according to the manufacturers instructions.
Inoculum density was adjusted to 1 McFarland standard and 240 l was dispensed
onto the centre of a 90 mm-diameter plate containing RPMI 1640 medium without
sodium bicarbonate and with L-glutamine (Sigma Aldrich Quimica, S.A., Madrid,
Spain), supplemented with 2% of glucose, and buffered to pH 7.0 with 0.165 M MOPS
(Sigma Aldrich Quimica). Bacto Agar (Difco, Soria Melguizo, Madrid, Spain) was added
at a final concentration of 1.5 g/100 ml. Plates were incubated at 30ºC and MICs were
interpreted at 48 and 72 h as previously described (1).
Strain typing: The five strains isolated from CM episodes were genotyped using
RFLPs generated by digesting total DNA samples to completion with the restriction
enzyme SacI (Promega corporation, Wi, USA) followed by hybridization with the
CNRE-1 probe (kindly provided by Dr S. Spitzer, New York, USA) as previously
described (3;19). Other three C. neoformans isolates recovered from different patients
were included as control strains. Hybridizations patterns were analyzed visually. DNA
fingerprinting using primers aimed to microsatellites, M13 and (GACA)4, applied to all
five strains, was performed to confirm their clonal origin.
Mutation detection: For the 14- sterol demethylase (ERG11) gene amplification,
primers were designed on the basis of the sequence of ERG11 gene from C.
neoformans (GenBank AF225914). Primer CnERG11A (5´ TCGTCGAACCATCTTTCG 3´)
was designed 83 bp upstream of the ATG initiation codon, and CnERG11B (5´
CGTCTATGACTTCATGACC 3´) was designed 73 bp downstream the termination codon.
The rest of the primers were designed to complite the full sequence of the gene. All the
primers used in the present work were synthesized by Pharmacia (Madrid, Spain). The
PCRs were carried out in a 50 l volume, containing 10 mM (NH4)2 SO4, 10 mM KCl,
20 mM Tris-Cl (pH 8.8), 2 mM MgSO4, 10 ng BSA, 0.1% Triton X-100, 250 M each of
dATP, dGTP, dCTP, and dTTP (Applied Biosystem, Madrid, Spain), 0.5 M of each
primer, 2.5 units of Taq DNA polymerase (Applied Biosystem) and 50 ng of genomic
DNA. Amplification was performed in a thermal cycler (Applied Biosystem) for one
cycle of 5 min at 94º C, then 30 cycles of 30 s at 94º C, 45 s at 48º C and 2 min at 72º
C, followed for one final cycle of 10 min at 72º C. The PCR products were analyzed by
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electrophoresis on 0.8 % agarose gels and visualized by transillumination after staining
them with ethidium bromide.
Cloning and plasmids: C. neoformans isolates were grown at 30ºC in YPD-Na (2%
glucose, 1 % yeast extract, 2% peptone, 3% ClNa), during 24 h at 150 rpm. DNA was
extracted as previously described (19). Escherichia coli JM109 was grown in Luria
Bertani (LB) medium (16), supplemented with ampicillin (100 g/ml), for propagation of
plasmids for DNA extraction. PCR products were purified by Spin cholumns-200
(Clontech, Madrid, Spain), and cloned into pGEM-T easy vector system (Promega,
Madrid, Spain). Inserts DNAs of recombinant plasmids were sequenced by the BigDye
terminator cycle sequencing ready reaction system (Applied Biosystem) according to
the manufacturer’s instructions. All the clones were sequenced on both strands. For
each Cryptococcus strain at least two inserts were analyzed. Sequence analysis was
performed on an ABI prism 377 DNA sequencer (Applied Biosystem) using the
sequencing facilities available at the Biopolymers Unit at Instituto de Salud Carlos III,
Majadahonda, Madrid (Spain).
Sequence analysis: The amino acid sequences of 14- sterol demethylase were
deduced from nucleotide sequences and analyzed using the MegAlign software
package (DNAstar, Inc., Lasergene, Madison, USA) run on a PC computer. The
multiple amino acids alignments were derived by CLUSTAL analysis (5). The full
nucleotide sequences of the ERG11 gene from C. neoformans var. grubii determined in
this work appear in the GenBank nucleotide sequence database under accession
number: AY265353.
Results and Discussion: Recurrent episodes of cryptococcal meningitis is a frequent
event among patients with AIDS. Several authors have described strains of C.
neoformans exhibiting resistance in vitro to FCZ. Usually, these isolates were
recovered from patients with recurrent episodes of cryptococcosis (4;11). However, the
development of resistance to azoles in this species remains infrequent (2). Herein, we
describe a case of cryptococcal meningitis in which FCZ resistance is developed.
Susceptibility testing of the five sequential isolates to antifungal agents is displayed in
Table 1. Regarding fluconazole MICs, isolates one to four were susceptible (MIC range
1-2 µg/ml) and a significant increase of the MIC was observed for the fifth isolate.
However, no variations in MICs of the other azole drugs tested (ITZ and VOR) were
detected in the sequential isolates. The strain exhibiting decreased susceptibility to
fluconazole (MIC 16 µg/ml) was isolated after 15 months of treatment, being the
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cumulative dose of fluconazole of 336 g. A similar event has been described by
Martinez et al. with C. albicans in a recurrent oropharyngeal candidiasis (OPC) (9). In
addition, Friese et al. reported a cryptococcal meningitis case in which the emergence
of a FCZ resistant strain (MIC of 64 g/ml) was documented after three episodes of
meningitis (4). The authors concluded that the development detection of FCZ
resistance isolate was probably due to the FCZ maintenance therapy. It is interesting to
note that our isolates and those studied by Friese et al. remained susceptible to other
triazole agents (Table 1).
All five strains isolated from the patient were genetically characterized by restriction
fragment length polymorphisms (RFLPs), followed by hybridization using the CNRE-1
probe. Hybridization patterns of strains CN-1 to CN-5 showed that these isolates were
clonally related (Figure 1). DNA fingerprinting using primers aimed to microsatellites,
M13 and (GACA)4, applied to all five strains demonstrated that the susceptible strains
and the resistant isolate were isogenic and it ratified their clonal origin (data not
shown).
In cases of OPC, the emergence of Candida isolates with decreased susceptibility to
azole agents is related to prolonged exposure of these antifungal agents (8;9;17). The
molecular mechanisms of resistance studied in C. albicans strains included: (i)
enhanced expression of efflux multidrug transporters genes causing decrease
intracellular antifungal drugs content, and (ii) changes in the interaction between the
azole antifungal agent and the 14- lanosterol demethylase (ERG11) enzyme due to
ERG11 modifications or its overproduction (8;9;17). In C. neoformans little is known
about mechanisms of azole resistance (12;20). Only recently, up-regulation of an ABC
transporter-encoding gene (CnAFR1) causing an active drug efflux mechanism has
been shown directly related to azole resistance in a C. neoformans strain (13). In this
study, the sequence of the ERG11 gene of sequential clinical isolates was analyzed in
order to know if we could find any ERG11 point mutations (6,9;18) responsible for FCZ
resistance, as has been previously described in C. albicans strains isolated from OPC
(8).
Fragments of 2147 bp containing the full ERG11 genomic sequence from all five
isolates were obtained by PCR amplification. A point mutation (g1855t) in the ERG11
gene was detected in the FCZ resistant isolate (CN-5) only. In order to verify that this
point mutation was not due to errors introduce by the PCR amplification, the ERG11
gene from all five isolates was newly amplified and sequenced a second time
confirming the single point mutation in the CN-5 isolate. This mutation is responsible for
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the amino acid substitution glycine 484 for serine (G484S), in the ERG11 deduced
protein sequence of C. neoformans. The G484 is a residue that forms part of the
conserved hemo-binding domain and is conserved in all cytochrome P450
ERG11/Cyp51 of yeasts and filamentous fungi (Figure 2). Several amino acid
substitution in ERG11 has been previously described in C. albicans (6, 8, 9, 18). Most
of these substitutions were present in enzyme domains highly conserved across yeasts
and filamentous fungi. The amino acid substitution present in the fifth isolate G484S
corresponds with the G464S of C. albicans ERG11 (Figure 2). Several studies have
demonstrated that this amino acid substitution detected in C. albicans ERG11 confers
a change in the orientation of the P450 hemo binding domain, leading to a decrease of
azole binding and a decrease of the catalytic activity of the enzyme (6, 18). In
sequential C. albicans strains recovered from OPC, has been demonstrated that this
substitution appeared in isolates with MIC of FCZ between 32-64 g/ml (9). Similarly, in
the C. neoformans isolates from the presented patient it was also clear that the
increase of FCZ MICs (from 2 to 16 g/ml) was matched to the G484S amino acid
substitution. However, the possibility of involvement of another concomitant molecular
mechanisms of resistance can not be disregarded.
We thank the Biopolymers Unit at Instituto de Salud Carlos III, Majadahonda, Madrid
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Figure 1.- Southern hybridization analysis of C. neoformans total cellular DNAs
digested with SacI and hybridized with the CNRE-1 probe. Lane CN-1 to CN-5 show
successive strains of recurrent episodes of cryptococcal meningitis. Lanes A, B and C
show DNAs of C. neoformans strains isolated from 3 different patients from the same
hospital and lane D corresponds to C. neoformans ATCC 90112. MW: Molecular
Weight (Kb).
Figure 2.- Alignment of the 33 amino acid residues of ERG11/Cyp51p sequences from
C. neoformans (CnCyp51-GenBank AAF35366), C. neoformans var. grubii
(CnN1Cyp51-GenBank AY265353), A. fumigatus (AfCyp51A-GenBank AAK73659 and
AfCyp51B-GenBank AAK73660), Leptosphaeria maculans (GenBank AAN28927)
Aspergillus nidulans (AnCyp51.-GeeBank AAF79204), Penicillium. italicum (PiCyp51.-
GenBank. CAA89824), Botryotinia fuckeliana (BcCyp51-GenBank AAF85983),
Erysiphe graminis (EgCyp51.-GeneBank AAC97606), Uncinula necator (UnCyp51-
GenBank AAC49812), Saccharomyces. cerevisiae (ScCyp51-GenBank AAA34546),
Candida glabrata (CgErg11-GenBank AAB02329), C. tropicalis (CtCyp51-GenBank
AAA53284), C. albicans (CaErg11.-GenBank AAF00598), and Ustilago maydis
(UmCyp51.-GenBank CAA88176). Identical residues between all the filamentous fungi
and yeast are bolded. The same 33 amino acid from the FCZ-resistant strain of C.
neoformans (CN-5) is at the bottom. Residue at position 484 is boxed.
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TABLE 1. Development of in vitro fluconazole (FCZ) resistance in the five sequential
clinical isolates of Cryptococcus neoformans. Table displays the time of follow-up at the
hospital, the cumulative dose of FCZ and the FCZ (ETEST and microdilution),
itraconazole (ITZ), voriconazole (VOR), flucytosine (FC) and amphotericin B (AMB)









FCZ(1) FCZ(2) ITZ(1) VOR(1) 5FC(1) AMB(1)
Initial (CN-1) 0 0 2 2 0.06 0.5 16 0.12
1st Relapse(CN-2) 2 0 1.5 2 0.12 0.06 8 0.25
2nd Relapse (CN-3) 3 24 2 1 0.06 0.06 16 0.12
3rd Relapse (CN-4) 9 180 1.5 4 0.12 0.12 32 0.25
4th Relapse (CN-5) 15 336 32 16 0.06 0.25 32 0.12
(1) Microdilution (2) E-TEST
